Skip to main content

Advertisement

SpringerLink
Log in

Preoperative Therapy for Extremity Soft Tissue Sarcomas

  • Sarcoma (SH Okuno, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

High-risk soft tissue sarcomas (STS) are defined as large (>5 cm), intermediate/high-grade tumors and can carry a >50 % risk of death from metastases. A regimen of preoperative chemoradiation immediately addresses issues of both local control and micrometastases and should be considered for patients with high-risk STS of the extremities. While acute wound healing complications are more likely to occur, these are most always manageable and reversible, as opposed to the long-term complications associated with higher radiation doses and larger fields required for post-operative therapy. Preoperative treatment also yields potential prognostic information from pathologic treatment response, and quantitative imaging methods hold promise to detect early treatment effect. Definitive evidence of survival benefit from neoadjuvant therapy has been elusive, but a large body of experience has accumulated at dedicated centers where this approach is utilized. Whenever possible, it is imperative that patients with high-risk STS be enrolled on well-designed clinical trials. Treatment planning and administration requires a coordinated multidisciplinary approach that should be undertaken in high-volume centers with expertise in the management of sarcomas.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. SEER Stat Fact Sheets: Soft tissue including heart cancer. [cited 2015 February 10]; Available from: http://seer.cancer.gov/statfacts/html/soft.html.

  2. Suit HD, Russell WO, Martin RG. Sarcoma of soft tissue: clinical and histopathologic parameters and response to treatment. Cancer. 1975;35(5):1478–83.

    Article  CAS  PubMed  Google Scholar 

  3. Lindberg RD et al. Conservative surgery and postoperative radiotherapy in 300 adults with soft-tissue sarcomas. Cancer. 1981;47(10):2391–7.

    Article  CAS  PubMed  Google Scholar 

  4. Yang JC et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol. 1998;16(1):197–203.

    CAS  PubMed  Google Scholar 

  5. Rosenberg SA et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg. 1982;196(3):305–15.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet. 1997;350(9092):1647–54.

  7. Weitz J, Antonescu CR, Brennan MF. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. J Clin Oncol. 2003;21(14):2719–25.

    Article  PubMed  Google Scholar 

  8. Woll PJ et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol. 2012;13(10):1045–54. This multicenter randomized trial of adjuvant doxorubicin/ifosfamide for resected STS found no survival benefit but includes an updated meta-analysis suggesting that patients with large, high-grade extremity sarcomas are most likely to benefit from chemotherapy.

    Article  CAS  PubMed  Google Scholar 

  9. Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults. Sarcoma Meta-analysis Collaboration (SMAC). Cochrane Database Syst Rev. 2000(2):CD001419.

  10. Pervaiz N et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113(3):573–81.

    Article  PubMed  Google Scholar 

  11. O’Sullivan B et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002;359(9325):2235–41.

    Article  PubMed  Google Scholar 

  12. Davis AM et al. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother Oncol. 2005;75(1):48–53.

    Article  PubMed  Google Scholar 

  13. Zagars GK et al. Preoperative vs. postoperative radiation therapy for soft tissue sarcoma: a retrospective comparative evaluation of disease outcome. Int J Radiat Oncol Biol Phys. 2003;56(2):482–8.

    Article  PubMed  Google Scholar 

  14. Wang D, et al. Significant reduction of late toxicities in patients with extremity sarcoma treated with image-guided radiation therapy to a reduced target volume: results of Radiation Therapy Oncology Group RTOG-0630 Trial. J Clin Oncol. 2015. doi:10.1200/JCO.2014.58.5828. This multicenter prospective phase II trial identified a significant reduction in late toxicities in patients with extremity STS treated with preoperative radiotherapy without an increased local recurrences.

  15. Judson I, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15(4):415-423.

  16. Antman KH et al. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol. 1989;7(1):126–31.

    CAS  PubMed  Google Scholar 

  17. O’Bryan RM et al. Phase II evaluation of adriamycin in human neoplasia. Cancer. 1973;32(1):1–8.

    Article  PubMed  Google Scholar 

  18. Bramwell VH et al. Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol. 1987;23(3):311–21.

    Article  CAS  PubMed  Google Scholar 

  19. Lorigan P et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol. 2007;25(21):3144–50.

    Article  CAS  PubMed  Google Scholar 

  20. Gortzak E et al. A randomised phase II study on neo-adjuvant chemotherapy for ‘high-risk’ adult soft-tissue sarcoma. Eur J Cancer. 2001;37(9):1096–103.

    Article  CAS  PubMed  Google Scholar 

  21. Grobmyer SR et al. Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann Oncol. 2004;15(11):1667–72.

    Article  CAS  PubMed  Google Scholar 

  22. Eilber FR et al. Limb salvage for skeletal and soft tissue sarcomas. Multidisciplinary preoperative therapy. Cancer. 1984;53(12):2579–84.

    Article  CAS  PubMed  Google Scholar 

  23. Eilber F et al. Preoperative therapy for soft tissue sarcoma. Hematol Oncol Clin North Am. 1995;9(4):817–23.

    CAS  PubMed  Google Scholar 

  24. Edmonson JH et al. Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor. Cancer. 2002;94(3):786–92.

    Article  CAS  PubMed  Google Scholar 

  25. DeLaney TF et al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Radiat Oncol Biol Phys. 2003;56(4):1117–27.

    Article  PubMed  Google Scholar 

  26. Mullen JT et al. Long-term follow-up of patients treated with neoadjuvant chemotherapy and radiotherapy for large, extremity soft tissue sarcomas. Cancer. 2012;118(15):3758–65. With a median follow-up of over 9 years, a single institution’s regimen of preoperative MAID chemotherapy with interdigitated radiation resulted favorable survival compared to historic controls.

    Article  PubMed  Google Scholar 

  27. Pisters PW et al. Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas. J Clin Oncol. 2004;22(16):3375–80.

    Article  CAS  PubMed  Google Scholar 

  28. Mack L et al. Preoperative chemoradiotherapy (modified Eilber protocol) provides maximum local control and minimal morbidity in patients with soft tissue sarcoma. Ann Surg Oncol. 2005;12(8):646–53.

    Article  PubMed  Google Scholar 

  29. Ryan CW et al. Histologic response of dose-intense chemotherapy with preoperative hypofractionated radiotherapy for patients with high-risk soft tissue sarcomas. Cancer. 2008;112(11):2432–9.

    Article  CAS  PubMed  Google Scholar 

  30. Kraybill WG et al. Long-term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall. Cancer. 2010;116(19):4613–21.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  31. Hong NJL et al. Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: a 10-year single institution retrospective study. Eur J Cancer. 2013;49(4):875–83.

    Article  CAS  Google Scholar 

  32. Meyer JM et al. Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates. Clin Cancer Res. 2013;19(24):6902–11. The addition of sorafenib 400 mg daily to a preoperative chemoradiation regimen was safe and effective, and DCE-MRI changes seen after 2 weeks of therapy correlated with histopathologic response at time of surgery.

    Article  CAS  PubMed  Google Scholar 

  33. Bedi M et al. Prognostic variables in patients with primary soft tissue sarcoma of the extremity and trunk treated with neoadjuvant radiotherapy or neoadjuvant sequential chemoradiotherapy. Radiat Oncol. 2013;8(1):60.

    Article  PubMed Central  PubMed  Google Scholar 

  34. Raval RR, et al. Evaluating the role of interdigitated neoadjuvant chemotherapy and radiation in the management of high-grade soft-tissue sarcoma: the Johns Hopkins experience. Am J Clin Oncol. 2014.

  35. Canter R et al. Phase I trial of neoadjuvant conformal radiotherapy plus Sorafenib for patients with locally advanced soft tissue sarcoma of the extremity. Ann Surg Oncol. 2014;21(5):1616–23.

    Article  PubMed Central  PubMed  Google Scholar 

  36. Lewin J et al. A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma. Br J Cancer. 2014;111(12):2254–61.

    Article  CAS  PubMed  Google Scholar 

  37. Okuno SMD, et al. Chemotherapy, irradiation, and surgery for function-preserving curative therapy of primary extremity soft tissue sarcomas: initial treatment with I-MAP and inhalation GM-CSF during preoperative irradiation and postoperatively. Am J Clin Oncol. 2014.

  38. Hoekstra HJ et al. A combination of intraarterial chemotherapy, preoperative and postoperative radiotherapy, and surgery as limb-saving treatment of primarily unresectable high-grade soft tissue sarcomas of the extremities. Cancer. 1989;63(1):59–62.

    Article  CAS  PubMed  Google Scholar 

  39. Goodnight Jr JE et al. Limb-sparing surgery for extremity sarcomas after preoperative intraarterial doxorubicin and radiation therapy. Am J Surg. 1985;150(1):109–13.

    Article  PubMed  Google Scholar 

  40. Denton JW et al. Preoperative regional chemotherapy and rapid-fraction irradiation for sarcomas of the soft tissue and bone. Surg Gynecol Obstet. 1984;158(6):545–51.

    CAS  PubMed  Google Scholar 

  41. Temple WJ et al. Neoadjuvant treatment in conservative surgery of peripheral sarcomas. Can J Surg. 1989;32(5):361–5.

    CAS  PubMed  Google Scholar 

  42. Wanebo HJ et al. Preoperative regional therapy for extremity sarcoma. A tricenter update. Cancer. 1995;75(9):2299–306.

    Article  CAS  PubMed  Google Scholar 

  43. Levine EA, Trippon M, Das Gupta TK. Preoperative multimodality treatment for soft tissue sarcomas. Cancer. 1993;71(11):3685–9.

    Article  CAS  PubMed  Google Scholar 

  44. Eilber FR et al. Intravenous (IV) vs. intraarterial (IA) Adriamycin, 2800r radiation and surgical excision for extremity soft tissue sarcomas: a randomized prospective trial. Proc Am Soc Clin Oncol. 1990;9:309a.

    Google Scholar 

  45. Frustaci S et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001;19(5):1238–47.

    CAS  PubMed  Google Scholar 

  46. Eilber FC et al. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol. 2001;19(13):3203–9.

    CAS  PubMed  Google Scholar 

  47. MacDermed DM et al. Primary tumor necrosis predicts distant control in locally advanced soft-tissue sarcomas after preoperative concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2010;76(4):1147–53.

    Article  PubMed Central  PubMed  Google Scholar 

  48. Andreou D et al. Prognostic relevance of the mitotic count and the amount of viable tumour after neoadjuvant chemotherapy for primary, localised, high-grade soft tissue sarcoma. Br J Cancer. 2015;112(3):455–60.

    Article  CAS  PubMed  Google Scholar 

  49. Tateishi U et al. PET/CT allows stratification of responders to neoadjuvant chemotherapy for high-grade sarcoma: a prospective study. Clin Nucl Med. 2011;36(7):526–32.

    Article  PubMed  Google Scholar 

  50. Vaynrub M et al. Prognostic value of necrosis after neoadjuvant therapy for soft tissue sarcoma. J Surg Oncol. 2015;111(2):152–7.

    Article  PubMed  Google Scholar 

  51. Mullen JT et al. Prognostic significance of treatment-induced pathologic necrosis in extremity and truncal soft tissue sarcoma after neoadjuvant chemoradiotherapy. Cancer. 2014;120(23):3676–82. Clinical outcomes for patients treated per single neoadjuvant chemoradiation protocol did not correlate with histopathologic response at time of surgery (≥95 % necrosis).

    Article  PubMed  Google Scholar 

  52. Radiation therapy with or without combination chemotherapy or pazopanib hydrochloride before surgery in treating patients with newly diagnosed non-rhabdomyosarcoma soft tissue sarcomas that can be removed by Surgery (PAZNTIS). [cited 2015 March 3]; Available from: https://clinicaltrials.gov/ct2/show/NCT02180867.

  53. Stacchiotti S et al. Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy. Cancer. 2012;118(23):5857–66.

    Article  PubMed  Google Scholar 

  54. Canter RJ et al. Radiographic and histologic response to neoadjuvant radiotherapy in patients with soft tissue sarcoma. Ann Surg Oncol. 2010;17(10):2578–84.

    Article  PubMed Central  PubMed  Google Scholar 

  55. Benz MR et al. FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res. 2009;15(8):2856–63.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  56. Eary JF et al. Sarcoma mid-therapy [F-18]fluorodeoxyglucose positron emission tomography (FDG PET) and patient outcome. J Bone Joint Surg. 2014;96(2):152–8. A prospective trial found that change in FDG-avidity between baseline and after two cycles of preoperative chemotherapy added prognostic value to patient outcome predictions.

    Article  PubMed Central  PubMed  Google Scholar 

  57. Wong P, et al. Combining targeted agents with modern radiotherapy in soft tissue sarcomas. J Natl Cancer Inst. 2014;106(11).

  58. Francis P et al. Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. BMC Genomics. 2007;8:73.

    Article  PubMed Central  PubMed  Google Scholar 

  59. Rajendran JG et al. [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging. 2003;30(5):695–704.

    Article  CAS  PubMed  Google Scholar 

  60. van der Graaf WT et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879–86.

    Article  PubMed  Google Scholar 

  61. Lee H-J et al. Inhibition of vascular endothelial growth factor A and hypoxia-inducible factor 1α maximizes the effects of radiation in sarcoma mouse models through destruction of tumor vasculature. Int J Radiat Oncol Biol Phys. 2015;91(3):621–30.

    Article  CAS  PubMed  Google Scholar 

  62. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58–62.

    Article  CAS  PubMed  Google Scholar 

  63. Sorafenib tosylate, combination chemotherapy, radiation therapy, and surgery in treating patients with high-risk stage IIB-IV soft tissue sarcoma. [cited 2015 March 6]; Available from: https://clinicaltrials.gov/ct2/show/NCT02050919.

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Lara E. Davis declares that she has no conflict of interest.

Christopher W. Ryan has received compensation from Pfizer, Onyx Pharmaceuticals, Janssen, EMD-Serono, Genentech, and Aveo for service as a consultant.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Oregon Health & Science University, 3181 SW Sam Jackson Park Road, L586, Portland, OR, 97239, USA

    Lara E. Davis M.D. & Christopher W. Ryan M.D.

Authors
  1. Lara E. Davis M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher W. Ryan M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lara E. Davis M.D..

Additional information

This article is part of the Topical Collection on Sarcoma

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Davis, L.E., Ryan, C.W. Preoperative Therapy for Extremity Soft Tissue Sarcomas. Curr. Treat. Options in Oncol. 16, 25 (2015). https://doi.org/10.1007/s11864-015-0346-4

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11864-015-0346-4

Keywords

Search

Navigation